BioTuesdays

Tag - parkinson’s disease

Stifel cuts Acorda Therapeutics PT to $1 from $2.50

Stifel reduced its price target for Acorda Therapeutics (NASDAQ:ACOR) to $1 from $2.50 and maintained its “hold” rating, citing lower than expected first quarter revenue for its Inbrija inhaled formulation of levodopa...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.